Navigation Links
Ranbaxy in Fray to Buy Merck's Generic Drugs Unit

Davos: After six global acquisitions last year, India's Ranbaxy Laboratories has entered the market again to acquire the generic drugs business of German// pharmaceuticals major Merck in a deal estimated at over $5 billion.

‘We are in talks with private equity funds to finance the deal,’ Ranbaxy's chief executive Malvinder Singh said on the margins of the annual meeting of the World Economic Forum (WEF) here. ‘We are being hounded by them for the takeover.’

According to Singh, the due diligence for the acquisition was expected to start next month. He, however, declined to give any financial details.

‘Merck makes sense for us since it would result in a major gain for us in the global generics business and a strategic fit for our activities,’ Singh said, adding: ‘I have been talking to some private equity funds even here.’

According to pharmaceutical industry sources, Merck's generics business records annual revenues around $2.5 billion and has the potential to more than triple Ranbaxy's turnover to around $3.75 billion after the acquisition.

The merger of Ranbaxy and Merck's generics business could result in a stable of 100 products in the US alone for drugs in diabetics, neurology, cardiovascular and neurology, among other areas.

The generics unit of the German major is the largest supplier in markets like Australia, France and Scandinavia.

Ranbaxy had acquired four companies in Europe last year, including Terapia of Romania, for $324-million. The company has approval from shareholders to sell bonds and shares worth $1.5 billion.

Source-IANSSRM
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... Greifensee, Switzerland (PRWEB) , ... January 23, 2017 ... ... many lab and production applications. However, choosing the right method is paramount to ... may occur more often in situations where multiple persons use the same equipment. ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and Research ... Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality research ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching ... diet. These resources have been developed for use by nutrition educators and ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an exotic journey ... world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago ... and moisturizing vegetal coral to create this gentle, velvety body cream to envelop the ...
(Date:1/21/2017)... ... ... Caronlab Australia, an Australian company known for health and beauty products such ... where it benefited from outstanding meetings with major retail buyers. , Caron Labs has ... this trade show, the company had the chance to demonstrate its products and provide ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... and PALMA, Spain , January ... S.L., a clinical-stage biopharmaceutical company focused on treatments ... patient has been enrolled in the Phase IIb ... for the treatment of cardiovascular calcification (CVC) in ... Most ESRD patients, in the last stage of ...
(Date:1/23/2017)... 2017 InDex Pharmaceuticals Holding AB (publ) today ... congress of the European Crohn,s and Colitis Organisation (ECCO). The ECCO ... focus on inflammatory bowel disease (IBD). The congress is held in ... ... to again having been selected to present data at the largest ...
Breaking Medicine Technology: